Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor approved for moderate-to-severe atopic dermatitis (AD) in adults. Objectives To evaluate absolute Eczema Area and Severity Index (EASI) and SCORing of Atopic Dermatitis (SCORAD) outcomes over 16 weeks and to link disease severity...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jacob P. Thyssen, Thomas Bieber, C. Elise Kleyn, Audrey Nosbaum, Susanne Grond, Helmut Petto, Elisabeth Riedl, Andreas Wollenberg
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Taylor & Francis Group 2023-12-01
Sarja:	Journal of Dermatological Treatment
Aiheet:	atopic dermatitis baricitinib eczema area and severity index (easi) scoring of atopic dermatitis (scorad)
Linkit:	http://dx.doi.org/10.1080/09546634.2023.2216322
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!